Evidence map›Paper›PMID 41749851›Full record

ArticleCancers2026

Effects of Eribulin on Epithelial-Mesenchymal Plasticity in Patient-Derived Breast Cancer Cultures and Excised Tissues.

Charles L Bidgood, Erika Morera, Binny Jaradi, Tirsa van Wyngaard, Anu T Koikalethu, Nathalie Bock, Veenoo Agarwal, Andrew D Redfern, Erik W Thompson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Charles L BidgoodCentre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.
Erika MoreraCentre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.ORCID 0009-0003-8985-9718
Binny JaradiCentre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.ORCID 0000-0002-1659-2034
Tirsa van WyngaardDepartment of Breast and Endocrine Surgery, Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia.
Anu T KoikalethuTranslational Research Institute, Brisbane, QLD 4102, Australia.
Nathalie BockTranslational Research Institute, Brisbane, QLD 4102, Australia.
Veenoo AgarwalMedical School, University of Western Australia, Crawley, WA 6009, Australia.ORCID 0000-0003-3951-2946
Andrew D RedfernMedical School, University of Western Australia, Crawley, WA 6009, Australia.ORCID 0000-0001-6728-8713
Erik W ThompsonCentre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.ORCID 0000-0002-9723-4924

Funding

National Breast Cancer Foundation RPG0118Tour de Cure RSP-106-2024
6 · The paper itself

Abstract

backgroundThe cytotoxic agent eribulin has been shown to promote EMT reversion, reduce treatment resistance, and potentially enhance responses to a range of therapeutic agents.

methodsWe examined the effects of eribulin in patient-derived breast cancer tissues and a phenotypically heterogeneous breast cancer cell line to assess EMT and chemotherapy response.

resultsNanostring-based analysis of EMT-associated gene expression in breast cancers from patients receiving standard-of-care TAC neoadjuvant chemotherapy compared to a cohort receiving neoadjuvant eribulin (NeoEribulin trial) showed markedly reduced expression of EMT markers in cancers treated with eribulin versus TAC. Through single-cell immunofluorescent imaging and analysis, we identified that HCC38 triple-negative breast cancer (TNBC) cells exhibited a shift towards an epithelial-like state marked by E-cadherin upregulation following acute eribulin exposure, but not with other chemotherapeutic agents. Investigation of primary breast cancer cultures derived from pre-neoadjuvant biopsies also revealed that HER2-enriched primary breast cancer cells displayed heightened chemosensitisation to doxorubicin (Adriamycin), which was not recapitulated in TNBC cultures.

conclusionsOur data highlight the presence of contextual parameters which govern the degree of EMT regulation by eribulin.

Indexed as

breast cancerchemoresistanceEMTeribulin

Identifiers

PMID41749851
PMCPMC12939509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.